Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Prostate cancer (PCa) is a leading cause of cancer deaths in the US.
• DNA damage response (DDR) gene mutations are prevalent in aggressive and therapy-resistant PCa.
• BRCA2 alterations are the most frequent (~13%) DDR mutations in advanced PCa.

Purpose of the Study:

• To review the function of BRCA2 in DNA repair.
• To examine the pathogenesis and progression of BRCA2-mutant PCa.
• To assess therapeutic strategies for BRCA2-altered PCa.

Main Methods:

• Literature review of studies on BRCA2 function, PCa progression, and treatment efficacy.
• Analysis of clinical data on PARP inhibitors, radiation therapy, and platinum-based chemotherapy in BRCA2-mutant PCa.
• Synthesis of information on germline and somatic alterations in DDR genes.

Main Results:

• BRCA2 plays a critical role in DNA double-strand break repair.
• BRCA2 mutations confer sensitivity to PARP inhibitors (PARPis).
• Olaparib and rucaparib are FDA-approved for advanced PCa with BRCA2 mutations.

Conclusions:

• BRCA2 alterations are key drivers in a subset of advanced PCa.
• Targeted therapies like PARPis offer significant benefit for patients with BRCA2-mutant PCa.
• Radiation therapy and platinum-based chemotherapy may also be effective options.